GC Wealth Management RIA LLC Increases Stock Position in Eli Lilly and Company $LLY

Key Points

• GC Wealth Management RIA LLC increased its stake in Eli Lilly and Company by 278.0% in the second quarter, acquiring an additional 8,820 shares to reach a total of 11,993 shares.
• Eli Lilly reported $6.31 earnings per share (EPS) for the last quarter, exceeding analyst expectations by $0.72, with revenues of $15.56 billion.
• Institutional investors own 82.53% of Eli Lilly's stock, indicating strong institutional confidence in the company's performance and outlook.

GC Wealth Management RIA LLC raised its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 278.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,993 shares of the company's stock after acquiring an additional 8,820 shares during the period. Eli Lilly and Company accounts for approximately 0.8% of GC Wealth Management RIA LLC's portfolio, making the stock its 16th largest position. GC Wealth Management RIA LLC's holdings in Eli Lilly and Company were worth $9,349,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in LLY. Hobbs Wealth Management LLC increased its holdings in shares of Eli Lilly and Company by 0.8% in the 1st quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock valued at $1,205,000 after acquiring an additional 12 shares during the period. Hixon Zuercher LLC increased its stake in Eli Lilly and Company by 0.7% in the first quarter. Hixon Zuercher LLC now owns 1,789 shares of the company's stock valued at $1,477,000 after purchasing an additional 12 shares during the period. O Brien Wealth Partners LLC raised its holdings in shares of Eli Lilly and Company by 25.5% in the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock valued at $49,000 after buying an additional 12 shares during the last quarter. Ascent Capital Management LLC raised its holdings in shares of Eli Lilly and Company by 2.5% in the first quarter. Ascent Capital Management LLC now owns 495 shares of the company's stock valued at $409,000 after buying an additional 12 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners boosted its stake in shares of Eli Lilly and Company by 2.7% during the first quarter. Tennessee Valley Asset Management Partners now owns 493 shares of the company's stock worth $407,000 after buying an additional 13 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $724.73 on Monday. The firm has a market capitalization of $685.93 billion, a price-to-earnings ratio of 47.37, a price-to-earnings-growth ratio of 1.01 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The business's 50 day simple moving average is $734.15 and its 200-day simple moving average is $766.60. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $937.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company's revenue was up 37.6% on a year-over-year basis. During the same period in the previous year, the firm posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, Director J Erik Fyrwald bought 1,565 shares of the company's stock in a transaction on Tuesday, August 12th. The stock was purchased at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the acquisition, the director owned 74,578 shares of the company's stock, valued at $47,903,686.74. The trade was a 2.14% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Gabrielle Sulzberger bought 117 shares of the business's stock in a transaction on Tuesday, August 12th. The shares were acquired at an average price of $641.18 per share, with a total value of $75,018.06. Following the transaction, the director owned 2,703 shares of the company's stock, valued at $1,733,109.54. The trade was a 4.52% increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 4,514 shares of company stock worth $2,894,841. Insiders own 0.14% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Leerink Partners restated a "market perform" rating and issued a $715.00 price target on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Berenberg Bank restated a "hold" rating and issued a $830.00 target price (down previously from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. DZ Bank upgraded shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. UBS Group cut their price target on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a report on Friday, August 8th. Finally, Erste Group Bank lowered Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and an average price target of $939.61.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.